Advertisement

Search Results for "Irritable Bowel Syndrome After Colon Resection"

13:20 EDT 24th May 2013 | BioPortfolio

Original Source: Anastomotic leakage after colonic resection.

The aim of this study is to present the diagnosis and management of anastomotic leakage after colon resection. Early diagnosis and urgent therapeutic intervention are required in order to avert life-threatening conditions that may be caused by anastomotic leakage. Minor leaks can be managed conservatively with successful outcomes. Major leaks should be managed operatively. In conclusion, leakage of colonic anastomosis remains the most serious complication after colon resection.

Matching Channels

Irritable Bowel Syndrome IBS

Irritable bowel syndrome (IBS) is a common but poorly understood chronic (long-term) condition where the normal functions of the bowel are disrupted. Symptoms of IBS include abdominal pain or discom...

Colorectal Cancer

Colon or Colorectal cancer is the growth of malignant polyps on the colon, bowel, anus and rectum. Growths in these locations can be benign, and removed by colonoscopy, but they have a risk of becom...

Short Bowel Syndrome

Resection of metastases

Surgical resection

Matching News

Health Tip: Keep Irritable Bowel Syndrome in Check

-- Irritable bowel syndrome can trigger cramps, abdominal pain, diarrhea and gas. But the cause is unclear, and an examination of the colon usually turns up no signs of the disease. The American Gastr...

Studying The Causes Of Irritable Bowel Syndrome - GENIEUR

Experts and scientists from 19 European countries are getting together to investigate the causes of IBS (irritable bowel syndrome) with the aim of better understanding the condition and improving diag...

New drug might help treat irritable bowel syndrome

(HealthDay)—A new drug significantly reduces the abdominal pain and constipation characteristic of certain types of irritable bowel syndrome, according to two new studies.

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced today that LINZESS (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult...

Irritable bowel syndrome clearly linked to gut bacteria

An overgrowth of bacteria in the gut has been definitively linked to Irritable Bowel Syndrome in the results of a new study which used cultures from the small intestine. This is the first study to use...

Lexicon wins fast-track status for irritable bowel syndrome drug

The FDA granted fast-track designation to LX1033, Lexicon Pharmaceuticals' experimental drug for irritable bowel syndrome.  -More- 

FDA approves Ironwood, Forest Labs bowel drug

The Food and Drug Administration on Thursday approved a new irritable bowel syndrome and constipation drug developed by Ironwood Pharmaceuticals Inc. and Forest Laboratories Inc.The agency approved L...

FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation

The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.

Matching PubMed Articles

Appendicitis and Benign Appendiceal Mucocele Presenting as Large Bowel Obstruction.

INTRODUCTION: Appendiceal mucocele is most commonly encountered incidentally during appendectomy. METHODS: We report a case of large bowel obstruction presenting as a closed loop with an appendiceal m...

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS.

Intestinal microbiota, pathophysiology and translation to probiotic use in patients with irritable bowel syndrome.

Probiotic agents have received growing attention in recent years as an alternative therapeutic tool in the management of irritable bowel syndrome. In this article, we will discuss the rationale that s...

A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome.

PURPOSE: To study the therapeutic effects of probiotic Escherichia coli Nissle 1917 (EcN) in irritable bowel syndrome (IBS) and identify subgroups benefiting most....

Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case-control study.

PURPOSE: The diagnosis of irritable bowel syndrome is symptom based, and colonoscopy is the most direct way to rule out organic colonic diseases. It is controversial on the necessity of colonoscopy fo...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement